Glitazone market
Executive Summary
Rezulin represented 30.6% of new prescriptions dispensed for glitazone diabetes products in February, compared to 40.6% for SmithKline Beecham/Bristol's Avandia and 28.7% for Lilly/Takeda's Actos, according to IMS Health data. Market share numbers were misreported in "The Pink Sheet" (March 27, p. 4)